Kura Oncology (Nasdaq: KURA) granted inducement stock options on June 1, 2026 to four new employees under its 2023 Inducement Option Plan. The awards cover 53,000 shares at an exercise price of $9.04 per share, vesting over four years under Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – KURA
-0.34%
3 alerts
-0.34%Session close to close
$817.17MMarket Cap
0.2xRel. Volume
In the Jun 5 session, KURA declined 0.34%, reflecting a mild negative market reaction.
Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
This announcement details a modest inducement grant of 53,000 nonstatutory stock options at $9.04 fo...
Analysis
This announcement details a modest inducement grant of 53,000 nonstatutory stock options at $9.04 for four new employees under Kura’s 2023 Inducement Option Plan, vesting over four years. It follows recent shareholder approval to add 6,500,000 shares to the equity plan and 2,500,000 to the ESPP, plus multiple director option grants. Investors monitoring dilution and governance may track future equity awards alongside upcoming clinical and commercial milestones.
Key Figures
Inducement option grant size:53,000 sharesNew employees granted:4 employeesOption exercise price:$9.04 per share+5 more
8 metrics
Inducement option grant size53,000 sharesNonstatutory stock options for new employees under 2023 Inducement Option Plan
New employees granted4 employeesRecipients of inducement stock option awards
Option exercise price$9.04 per shareClosing price of common stock on June 1, 2026
Q1 2026 results including KOMZIFTI launch metrics, revenue, and net loss details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent positive clinical and data updates for KURA have often been followed by negative price reactions over the next day, while event-related or mixed financial news has seen more supportive or mixed trading.
Recent Company History
Over the last month, Kura Oncology has highlighted several clinical milestones, including strong Phase 1a data for darlifarnib combinations and updated ziftomenib results in AML, yet shares fell after these updates (-7.47%, -3.51%, -0.72%). An investor conference announcement on May 19, 2026 coincided with a 10.27% rise. Q1 2026 earnings on May 12, 2026 showed initial KOMZIFTI revenue but a sizeable net loss, with a modest decline of -2.07%. Today’s inducement grants fit into this broader pattern of active pipeline and expanding equity incentives.
Key Terms
nasdaq listing rule 5635(c)(4), nonstatutory stock options, inducement option plan
3 terms
nasdaq listing rule 5635(c)(4)regulatory
"approved the stock options as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
nonstatutory stock optionsfinancial
"granted inducement awards consisting of nonstatutory stock options to purchase 53,000 shares"
A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.
inducement option planfinancial
"to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended."
A plan that grants stock options to newly hired or newly promoted employees and executives as a hiring or retention incentive, like offering a share of future upside instead of a higher salary. For investors this matters because these options can dilute existing shares, create ongoing compensation costs, and signal how management is being incentivized to grow the business—similar to giving a performance-based bonus that ties pay to company results.
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 53,000 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to $9.04 per share, the closing price of the Company’s common stock on June 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.
About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
What inducement stock options did Kura Oncology (KURA) grant on June 1, 2026?
Kura Oncology granted nonstatutory stock options to purchase 53,000 shares of common stock to four new employees. According to the company, these options were issued under its 2023 Inducement Option Plan as inducement awards tied to employment.
What is the exercise price of Kura Oncology (KURA) inducement options granted in June 2026?
The inducement options have an exercise price of $9.04 per share. According to Kura Oncology, this price equals the closing price of its common stock on June 1, 2026, the grant date for these awards.
How do Kura Oncology (KURA) June 2026 inducement options vest?
The inducement options vest over four years. According to Kura Oncology, 25% of the shares vest on the one-year anniversary of the vesting commencement date, with the remaining shares vesting monthly over the following 36 months, subject to continued service.
Why did Kura Oncology (KURA) issue inducement grants under Nasdaq Rule 5635(c)(4)?
Kura Oncology approved these options as inducement awards material to new employees’ employment. According to the company, the grants comply with Nasdaq Listing Rule 5635(c)(4), which allows equity awards outside shareholder-approved plans for new hires.
How many employees received Kura Oncology (KURA) inducement stock options in June 2026?
Four new employees received inducement stock option awards. According to Kura Oncology, these employees were granted options covering a total of 53,000 shares under the company’s 2023 Inducement Option Plan, as amended.
Under which plan were Kura Oncology (KURA) June 2026 inducement options granted?
The inducement options were granted under Kura Oncology’s 2023 Inducement Option Plan, as amended. According to the company, the awards are also governed by the terms and conditions of individual stock option agreements for each grant.
